|
Press
Releases |
15 January 2010 |
| Quintessence Biosciences to Present at Keystone Symposia’s RNA Silencing Conference (PDF) |
| |
13 January 2010 |
| Quintessence Biosciences Announces Expansion to The University of Texas M. D. Anderson Cancer Center ofthe Cancer Clinical Trial for QBI-139 (PDF) |
| |
6
January 2010 |
| Quintessence Biosciences to Present at OneMedForum 2010 (PDF) See an interview with Laura Strong, President and COO of Quintessence, at the OneMedForum 2010 (link) |
| |
8 December 2009 |
| Quintessence President and COO, Laura Strong, Talks with Joan Gillman and Jody Glynn Patrick from In Business with Joan and Jody on Madison WTDY 1670 (link) |
| |
13
November 2009 |
| Quintessence Biosciences to Present QBI-139 Data at International Cancer Conference(PDF) |
| |
3
September 2009 |
| Quintessence Gets Support from the National Cancer Institute for Next Generation EVade™ RNases (PDF) |
| |
26
March 2009 |
| Patients
Now Enrolling in Phase I Human Trial for Quintessence Biosciences
Cancer Drug, QBI-139 (PDF) |
| |
5
December 2008 |
| Quintessence
Biosciences Cancer Drug, QBI-139, Clears FDA Review to Start Phase
I Human Trial (PDF). |
| |
23
October 2008 |
|
Quintessence Biosciences Present Efficacy Data for Next Generation
EVade™ Ribonucleases at Cancer Meeting (PDF) |
| |
6
October 2008 |
| Federal
Contract Awarded to Quintessence Biosciences (PDF)
Funding will support development of Next Generation EVade™
Ribonuclease Drug Candidates. |
| |
14
April 2008 |
Quintessence
Biosciences, Inc. Presents IND-Enabling Toxicology Data at Cancer
Meeting (PDF)
At the Annual Meeting of the American Association for Cancer
Research today, Quintessence Biosciences presented the results
of the IND-enabling toxicology
studies for the Company’s lead cancer drug candidate, QBI-139. |
| |
5 February 2008 |
| Althea
Technologies Chosen by Quintessence Biosciences to Produce Lead
Protein Oncology Drug (PDF)
Althea Technologies, Inc., a leading provider of innovative technologies
and services for pharmaceutical development and manufacturing,
announced today that is has been awarded a contract from Quintessence
Biosciences under a manufacturing supply agreement to produce
the firm’s first drug candidate. |
| |
30 November 2007 |
| Quintessence
Biosciences, Inc. Announces Award of Two Federal Grants to Support
Development of EVade™ Ribonuclease Products
(PDF) The
National Cancer Institute awarded Quintessence Biosciences two
Phase 1 Small Business Innovation Research grants. |
| |
22 October 2007 |
| Quintessence
Biosciences, Inc. Presents Additional Data on Lead Candidate (PDF)
Quintessence Biosciences presented information about
the company’s lead candidate QBI-139 at the International
Conference on Molecular Targets and Cancer Therapeutics - the
premier international meeting featuring novel cancer therapeutics. |
| |
16
April 2007 |
| Quintessence
Biosciences, Inc. Presents Pre-clinical Toxicology Data at Cancer
Meeting (PDF)
At the Annual Meeting of the American Association for Cancer Research
today, Quintessence Biosciences presented pre-clinical toxicology
data on the performance of the Company’s lead cancer drug
candidate, QBI-139 for treatment of patients with solid tumors. |
| |
8
February 2007 |
| Quintessence
Biosciences, Inc. Names Laura Strong, Ph.D. as President
(PDF)
Quintessence Biosciences today announced the appointment of Laura
Strong, Ph.D. to the position of the Company’s President
and Chief Operating Officer. |
| |
9
November 2006 |
| Quintessence
Biosciences Confirms Selection of EVade™ Ribonuclease Cancer
Treatment for Late Stage Pre-Clinical Studies (PDF)
Quintessence Biosciences, Inc. today confirmed the selection of
a compound from its proprietary EVade™ Ribonuclease program
for advancement to pre-clinical testing and human clinical trials. |
| |
19
April 2005 |
| Quintessence
Biosciences Announces Start of Non-Clinical Studies on Lead Candidate
QBI-139 at the 2005 Annual Meeting of the American Association
of Cancer Research (PDF) |
| |
17
September 2004 |
| Quintessence
Biosciences to present at BioContact Quebec 2004 (PDF)
Quintessence Biosciences, Inc. announced today that it will present
at BioContact Quebec 2004, a biopharmaceutical partnership symposium
at 4:00 p.m. eastern time on October 7, 2004. |
| |
18
June 2004 |
|
Quintessence Biosciences, Inc. names Scientific Advisory
Board (PDF)
Howard H. Bailey, Thomas J. Burke, Anthony J. Clemento Jr., and
Paul M. Sondel have agreed to join the Founders, Laura L. Kiessling
and Ronald T. Raines on the Scientific Advisory Board. |
| |
25
July 2003 |
| Three
Prominent Business Leaders to Assist Quintessence Biosciences,
Inc. (PDF)
Christopher Hornung (President and CEO of Pacific Cycle, Madison),
Theodore R. ("Ted") Rolfs (Managing Director of Red
Top Capital, Milwaukee), and David G. Walsh (partner of the Madison
office of Foley & Lardner) have agreed to join the Quintessence
Biosciences, Inc. Business Advisory Board. |
| |
22
May 2003 |
| Quintessence
Biosciences, Inc. secures $3 million in financing (PDF)
Quintessence Biosciences, Inc. of Madison announced today that
it has closed on transactions that will bring over $3 million
of new financing to the biotechnology company. |
| |
